Skip to content

Sarepta Therapeutics, Inc.

SRPT

CIK 0000873303

← back to feed
Revenue (TTM)
$1.83B
+4.3% YoY Q1 May 2026
Net Income (TTM)
−$99.6M
−715.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.63
−686.0% YoY Q1 May 2026
Gross Margin
-1.6%
Q1 May 2026
Operating Margin
3.8%
Q1 May 2026
Net Margin
-5.5%
Q1 May 2026
Free Cash Flow (TTM)
−$1.33B
Q1 May 2026
Cash
$464.45M
Q1 May 2026
Total Debt
$1.45M
Q1 May 2026
Shares Outstanding
105.58M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings